The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×2•Originally published 23 April 2026•Updated 23 April 2026•

1 min read

Roche Q1 Sales Decline as Foreign Exchange Headwinds Offset Growth

Key Facts

1Swiss drugmaker Roche reported a decline in first-quarter sales due to negative foreign exchange effects.

2The company's sales rose at constant exchange rates despite the nominal decline.

Swiss pharmaceutical giant Roche reported a decline in reported first-quarter sales due to negative foreign exchange effects, despite achieving a robust 6% growth at constant exchange rates. The company's results surpassed analyst expectations, leading management to officially confirm its full-year financial guidance. This operational growth was primarily driven by high demand for innovative medicines and a strong performance in the diagnostics division. However, Roche's legacy portfolio continues to face headwinds from increasing biosimilar competition. Investors remain focused on the company's ability to sustain momentum in its core healthcare portfolio while navigating both currency volatility and the erosion of older product revenues.

about 1 month ago

Version History

Version 2about 1 month ago

What changed: Added specific 6% CER growth figure, noted the earnings beat, and included the impact of biosimilar competition on legacy products.

Version 1about 1 month ago

What changed: The story was updated to include the company's confirmation of its full-year financial guidance and to identify innovative medicines and diagnostics as the primary growth drivers.